Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis

Volume: 11, Pages: 203636131882541 - 203636131882541
Published: Jan 1, 2019
Abstract
Cancers of the small bowel could account for less than 5% of all gastrointestinal malignancies. Of these tumors, adenocarcinomas were the major histologic subtype and generally carried a poor prognosis. High expression of vascular epithelial growth factor (VEGF) could be seen in small bowel adenocarcinomas. A systematic review was conducted here to determine if bevacizumab, a recombinant humanized antibody against VEGF, could offer clinical...
Paper Details
Title
Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis
Published Date
Jan 1, 2019
Volume
11
Pages
203636131882541 - 203636131882541
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.